Investment Opportunity – MediVIE Tech

MediVIE Tech is a French MedTech developing PULSAR, a medical-grade wearable solution for continuous vital-sign monitoring in hospitals and remote care.

In just two and a half years, MediVIE Tech has moved from an initial clinical need to an industrializable solution, developed with a lean team of four full-time people. We have already de-risked several key dimensions of the project: product-market need, clinical relevance, quality system, technical development and industrialization pathway.

Our Quality Management System is ISO 13485 certified, and we have already started our certification roadmap under the European medical device framework. PULSAR has been co-created with physicians and nurses to ensure that the product addresses real clinical workflows, usability constraints and monitoring needs.

We have also started the industrialization phase with pre-series production, bringing the product closer to scalable manufacturing. The next major step is clinical testing as part of our certification pathway. Following these tests, our objective is to submit the technical documentation required for medical device certification.

We are now raising funds to complete the certification roadmap, finalize clinical validation, support industrialization, and prepare the launch of our first commercial deployments.

PULSAR is designed to address a major clinical blind spot: the lack of continuous monitoring for patients outside intensive care units. By continuously capturing key physiological parameters and turning them into actionable insights, PULSAR aims to help healthcare teams detect patient deterioration earlier, support clinical decision-making and improve patient follow-up across hospital wards, post-operative care, cardiology, pneumology, home hospitalization and remote patient monitoring.

At VivaTech 2026, we are looking to connect with investors and strategic partners interested in supporting a MedTech company that has already significantly de-risked its path from clinical need to industrializable medical-grade solution.